These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9272371)
1. Public health application of acellular pertussis vaccines. Hadler SC; Orenstein WA Dev Biol Stand; 1997; 89():355-61. PubMed ID: 9272371 [No Abstract] [Full Text] [Related]
2. Pertussis in adolescents and adults: should we vaccinate? Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232 [TBL] [Abstract][Full Text] [Related]
3. Acellular pertussis vaccines: the next step. Halperin SA Dev Biol Stand; 1997; 89():363-5. PubMed ID: 9272372 [No Abstract] [Full Text] [Related]
4. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. America Academy of Pediatrics Commitee on Infectious Diseases Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131 [TBL] [Abstract][Full Text] [Related]
5. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Dylag AM; Shah SI Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489 [TBL] [Abstract][Full Text] [Related]
6. Epidemiology of pertussis and use of acellular pertussis vaccines in Japan. Kuno-Sakai H; Kimura M Dev Biol Stand; 1997; 89():331-2. PubMed ID: 9272368 [No Abstract] [Full Text] [Related]
7. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR; Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582 [TBL] [Abstract][Full Text] [Related]
8. Public health implications: United Kingdom. Miller E Dev Biol Stand; 1997; 89():367-8. PubMed ID: 9272373 [No Abstract] [Full Text] [Related]
9. Efficacy trial of acellular pertussis vaccines; trial I. Olin P Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569 [No Abstract] [Full Text] [Related]
10. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers. Greer AL; Fisman DN Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056 [TBL] [Abstract][Full Text] [Related]
11. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. Wilson TR J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630 [TBL] [Abstract][Full Text] [Related]
12. Japanese experience with 60 million doses of acellular pertussis vaccines. Sato H Dev Biol Stand; 1997; 89():327-9. PubMed ID: 9272367 [No Abstract] [Full Text] [Related]
13. [[Health and economic benefits of mandatory regular vaccination in the Slovak Republic. III. Diphtheria, tetanus and pertussis] ]. Hudecková H; Straka S; Szilágyiová M; Rusnáková S Epidemiol Mikrobiol Imunol; 2000 Nov; 49(4):153-7. PubMed ID: 11188762 [TBL] [Abstract][Full Text] [Related]
14. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA. Gidengil CA; Sandora TJ; Lee GM Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of a three-component acellular pertussis vaccine (DTaP) in early childhood after household exposure to "typical" (WHO-defined) pertussis. Schmitt HJ Dev Biol Stand; 1997; 89():67-9. PubMed ID: 9333573 [No Abstract] [Full Text] [Related]
17. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants. Beloradsky BH Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574 [No Abstract] [Full Text] [Related]